Investment Thesis
BDSX is a pre-profitability medical diagnostics company with severe operational losses (-30.5% net margin) and negative free cash flow (-$10.2M), despite 24% revenue growth indicating poor earnings quality. Extreme leverage (5.48x Debt/Equity) combined with negative interest coverage and ~2.5 years of cash runway at current burn rates creates significant solvency risk without an imminent profitability inflection.
Strengths
- Strong revenue growth of 24.1% YoY demonstrates market demand for diagnostics services
- Adequate near-term liquidity with $25.6M cash and 2.82x current ratio
- Operates in growing medical laboratory services sector with structural tailwinds
Risks
- Deeply unprofitable with -30.5% net margin and deteriorating quality of earnings despite revenue growth
- Negative operating cash flow (-$10.2M) and negative free cash flow (-40.1% FCF margin) indicate core business model stress
- Dangerously overleveraged with 5.48x Debt/Equity ratio, $50M long-term debt, and negative interest coverage (-3.1x) preventing debt service from operations
- Limited cash runway of approximately 2.5 years at current burn rate; requires capital raise or profitability inflection
Key Metrics to Watch
- Operating cash flow trend and path to positive free cash flow generation
- Gross margin and operating margin expansion toward breakeven
- Debt refinancing success and leverage reduction progress relative to cash burn
Financial Metrics
Revenue
25.6M
Net Income
-7.8M
EPS (Diluted)
$-0.81
Free Cash Flow
-10.2M
Total Assets
94.6M
Cash
25.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-24.3%
Net Margin
-30.5%
ROE
-85.3%
ROA
-8.2%
FCF Margin
-40.1%
Balance Sheet & Liquidity
Current Ratio
2.82x
Quick Ratio
2.82x
Debt/Equity
5.48x
Debt/Assets
90.4%
Interest Coverage
-3.14x
Long-term Debt
50.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-06T20:06:03.403013 |
Data as of: 2026-03-31 |
Powered by Claude AI